Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma - Wikidata - awgldk - TriplyDB

Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma

Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma

http://www.wikidata.org/entity/Q35939421

about

Retargeting Strategies for Oncolytic Herpes Simplex Viruses Progresses towards safe and efficient gene therapy vectors Oncolytic herpes simplex virus-based strategies: toward a breakthrough in glioblastoma therapy Preclinical therapy of disseminated HER-2⁺ ovarian and breast carcinomas with a HER-2-retargeted oncolytic herpesvirus.The Engineering of a Novel Ligand in gH Confers to HSV an Expanded Tropism Independent of gD Activation by Its Receptors Gene therapy for malignant glioma.Designing Herpes Viruses as Oncolytics.Role of Btg2 in the progression of a PDGF-induced oligodendroglioma model The art of gene therapy for glioma: a review of the challenging road to the bedside Systemic delivery of HER2-retargeted oncolytic-HSV by mesenchymal stromal cells protects from lung and brain metastases.Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy Effective treatment of an orthotopic xenograft model of human glioblastoma using an EGFR-retargeted oncolytic herpes simplex virus Combinatorial strategies for oncolytic herpes simplex virus therapy of brain tumors.A Strategy for Cultivation of Retargeted Oncolytic Herpes Simplex Viruses in Non-cancer Cells.Oncolytic potency of HER-2 retargeted VSV-FH hybrid viruses: the role of receptor ligand affinity.Retargeting of herpes simplex virus (HSV) vectors.A cadherin switch underlies malignancy in high-grade gliomas.Immune and viral therapies for malignant primary brain tumors.Efficacy of HER2 retargeted herpes simplex virus as therapy for high-grade glioma in immunocompetent mice.Dual Ligand Insertion in gB and gD of Oncolytic Herpes Simplex Viruses for Retargeting to a Producer Vero Cell Line and to Cancer Cells.A fully-virulent retargeted oncolytic HSV armed with IL-12 elicits local immunity and vaccine therapy towards distant tumors HSV as A Platform for the Generation of Retargeted, Armed, and Reporter-Expressing Oncolytic Viruses

P2860

Q26765439-85554C55-B4D8-4BD8-99CE-45E9F3D5A5EA Q26781432-D71D5691-FB7C-4DA9-AB0A-CF812D3CC032 Q26998111-287562D5-8F9E-4899-BE57-C45A6D2ED2AE Q34574879-FD208533-40A7-4E70-BFEA-D3C758038CAC Q35638350-9A4DCD28-9045-49CA-B4A5-33D4A2B184B3 Q35673628-BB744942-6A94-4062-8C57-1864C19A2325 Q36142487-3C46F95C-F359-41CB-8161-0F176D0A4AC0 Q36432526-EBAE7FC7-D11B-4D43-906B-328BA86585D7 Q36527593-BF874917-6EE6-472B-A98C-E13A53D0B527 Q36544212-4BE08BBD-5ECA-4DBC-AFD9-B3255DC2F32D Q36644898-72674BE5-B159-469C-B969-F4A796C21C01 Q36659325-9D0E4673-3840-4663-BD5A-564695E1D847 Q36849213-0DD62809-A872-4225-AFE4-92B1EC4059BC Q38714321-82DC933B-20DD-4FFD-9E83-49C588428D3D Q38845078-A363D692-A6E3-4BF9-AA8E-2EB137FCA79A Q38950892-FE00732A-91BF-4BAF-B813-282B67771F8E Q38992057-48835C9D-D7EA-47BC-B712-61F43CF743BD Q39168899-60754A90-7D51-41C6-AC41-EE2160CA4962 Q45354666-CB4D1E37-9624-4977-A892-F8D17736A62A Q47562626-0303FB12-19BE-4162-A4DC-A3B7BA4D440B Q56348401-5A6DB8B9-8906-4047-8824-1D4579218DE3 Q56378150-D3DF6BD3-ADC6-48A4-AE70-D3CC00CAA85C

P2860

Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma

http://www.wikidata.org/entity/Q35939421

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Replication-competent herpes s ...... therapy for high-grade glioma

@ast

Replication-competent herpes s ...... therapy for high-grade glioma

@en

type

label

Replication-competent herpes s ...... therapy for high-grade glioma

@ast

Replication-competent herpes s ...... therapy for high-grade glioma

@en

prefLabel

Replication-competent herpes s ...... therapy for high-grade glioma

@ast

Replication-competent herpes s ...... therapy for high-grade glioma

@en

P1433

Q35939421-F565373B-2A97-48D8-8C4D-65697138428F

P1476

Q35939421-3CDC30AA-1C23-40F3-B098-716C980C8B5D

P2093

Q35939421-43A6D7B0-ABB7-42E2-B34A-75AE77C9C1CF

Q35939421-79EF7B1A-94F4-40BA-9017-70316104E007

Q35939421-9DFC156E-89AD-45EB-94BA-2F725C850BA9

Q35939421-A9E60623-6D27-4566-9117-F3E3C8C87CC5

Q35939421-D0F9FC77-687B-41D4-A9CB-0B690752CEEC

P2860

Q35939421-00ED8667-86BA-4F6D-A2D5-389E44FD1B2D

Q35939421-01DCC858-5DF7-435C-B7C7-2B6E1AB459C4

Q35939421-048A6E66-D2B5-42A5-9748-D11BE49C5E74

Q35939421-06B1CC29-8C1A-4106-81A8-C5517332F680

Q35939421-099335BA-64A1-42AF-8928-5DFE1FDAD4A6

Q35939421-15000DDE-506C-4FE9-BC0B-81EA437B0FE9

Q35939421-16DA0C77-0CA1-425B-A518-6416BA0FE707

Q35939421-1AACFC8E-E19F-4142-B20B-B82DF2D81AB7

Q35939421-2061F7F4-67DB-4BBB-B85C-B389E417CC87

Q35939421-2CA73882-A50F-47CD-B0BA-BFA3D211B198

P304

Q35939421-86BEF959-F9CE-42A2-AF24-09C89C0C91D6

P31

Q35939421-8CC389E9-57CC-40D1-8763-18335D2CE813

P356

Q35939421-18E48A11-4ABD-4C9A-A37B-DADE0AD97EAF

P433

Q35939421-B7A9CDE5-B4C2-4A11-8FF1-178D81F66D86

P478

Q35939421-99ED53D1-D764-4D51-863A-AD732A687156

P50

Q35939421-7E62D079-FB01-4DDB-BE6E-1F967BF07810

Q35939421-B35C6BFF-98D0-442F-8443-FF3BC7FE52BA

Q35939421-C1E360AE-D9CB-4E20-A7CB-24872A008D49

P577

Q35939421-15304028-B75A-4024-933E-81FBFC0020C5

P5875

Q35939421-5FA31DA1-9BCB-4BFC-8745-07E5E474F739

P698

Q35939421-34501911-C30F-4019-938A-44A84CCDAA05

P932

Q35939421-B26076A8-408C-460E-B429-0901A62D1E82

P356

P1433

Molecular Therapy

P1476

Replication-competent herpes s ...... therapy for high-grade glioma

@en

P2093

Eleonora Gambini

http://www.w3.org/2001/XMLSchema#string

Elisa Reisoli

http://www.w3.org/2001/XMLSchema#string

Irene Appolloni

http://www.w3.org/2001/XMLSchema#string

Laura Menotti

http://www.w3.org/2001/XMLSchema#string

Paolo Malatesta

http://www.w3.org/2001/XMLSchema#string

P2860

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival.

Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM

PDGF-B-driven gliomagenesis can occur in the absence of the proteoglycan NG2

Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas.

Genetically engineered HSV in the treatment of glioma: a review.

Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer.

Engineered herpes simplex virus 1 is dependent on IL13Ralpha 2 receptor for cell entry and independent of glycoprotein D receptor interaction.

A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor.

P304

994-1001

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/MT.2012.22

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

20

http://www.w3.org/2001/XMLSchema#string

P50

Gabriella Campadelli-Fiume

Valentina Gatta

VALENTINA GATTA

P577

2012-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221851226

http://www.w3.org/2001/XMLSchema#string

P698

22354378

http://www.w3.org/2001/XMLSchema#string

P932

3345974

http://www.w3.org/2001/XMLSchema#string